Ompenaclid

Ompenaclid (RGX-202) is an oral small-molecule SLC6A8 transporter inhibitor. Ompenaclid robustly inhibits creatine import in vitro and in vivo, reduces intracellular phosphocreatine and ATP levels, and induces tumor apoptosis. Ompenaclid can be used for the research of cancer and duchenne muscular dystrophy[1][2].

Product Specifications

CAS Number

[353-09-3]

Product Name Alternative

RGX-202; 3-Guanidinopropionic acid

UNSPSC

12352211

Hazard Statement

H315, H319, H335

Target

Apoptosis; Endogenous Metabolite

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ompenaclid.html

Concentration

10mM

Purity

99.94

Solubility

DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : ≥ 50 mg/mL

Smiles

O=C(O)CCNC(N)=N

Molecular Formula

C4H9N3O2

Molecular Weight

131.14

Precautions

H315, H319, H335

References & Citations

[1]Kurth I, et al. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Sci Adv. 2021 Oct 8;7 (41) :eabi7511.|[2]Creisméas A, et, al. TRPC1 and TRPC3 involvement in DMD physiopathology and as potential targets for treatment in complement to rAAV-microdystrophin. 2021 Oct 1;13.